Cape Verde vs Peru: Average cost of multi drug-resistant tuberculosis treatment
Cape Verde
500 constant 2022 US$
in 2024
Peru
570 constant 2022 US$
in 2024
Cape Verde rank
78th
Peru rank
75th
Average cost of multi drug-resistant tuberculosis treatment over time
- Cape Verde
- Peru
How they compare
Peru currently reports 570 constant 2022 US$ against 500 constant 2022 US$ in Cape Verde, a difference of 70 constant 2022 US$.
That makes Peru's figure about 1.1 times Cape Verde's.
The two have swapped places 3 times across 8 shared years of data; in 2017 it was Cape Verde ahead.
Cape Verde ranks 78th and Peru ranks 75th of 92 countries.
Across the 2 decades both report, Cape Verde averaged higher in 1 and Peru in 1.
Head to head by decade
| Decade | Cape Verde | Peru | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,500 constant 2022 US$ | 1,408 constant 2022 US$ | 92 constant 2022 US$ | Cape Verde |
| 2020s | 1,100 constant 2022 US$ | 1,327 constant 2022 US$ | 227 constant 2022 US$ | Peru |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Cape Verde or Peru?
- Peru, at 570 constant 2022 US$ against 500 constant 2022 US$ in Cape Verde as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Cape Verde and Peru?
- 70 constant 2022 US$, with Peru ahead.
- How many years of comparable data are there for Cape Verde and Peru?
- 8 years are reported by both, from 2017 to 2024.
- How do Cape Verde and Peru rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Cape Verde ranks 78th and Peru ranks 75th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.